Clinical Trial: Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects

U.S., July 14 -- ClinicalTrials.gov registry received information related to the study (NCT07697443) titled 'Clinical Trial of TQB3126 for Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy in Breast Cancer Subjects' on July 07.

Brief Summary: The trial comprises Phase I dose escalation/expansion and Phase II combination therapy. Using a multicenter, open-label, non-randomized design, breast cancer patients will receive TQB3126 to assess its safety, tolerability, pharmacokinetics and preliminary efficacy.

Study Start Date: Aug., 2026

Study Type: INTERVENTIONAL

Condition: Breast Cancer

Intervention: DRUG: TQB3126

TQB3126 is a targeted protein degrader.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Chia Tai Tianqing P...